Почетна › Рак на бели дробови со не-мали клетки › Тексас › San Antonio
Клинички испитувања за Рак на бели дробови со не-мали клетки во San Antonio, TX
59 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу San Antonio (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study of ZW251 in Participants With Advanced Solid Tumors
Се регрутираФаза 1
- START San Antonio, San Antonio
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- START - San Antonio, San Antonio
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Се регрутираФаза 1
- University of Texas San Antonio (UTSA), San Antonio
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Се регрутираФаза 3
- Texas Oncology - San Antonio Medical Center, San Antonio
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Се регрутираФаза 3
- Texas Oncology - San Antonio, San Antonio
- Local Institution - 0381, San Antonio
A Study of PHN-012 in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- PHN-012-001 Site, San Antonio
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Texas Oncology San Antonio Northeast, San Antonio
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Се регрутираФаза 3
- USO - Texas Oncology - San Antonio, San Antonio
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Се регрутираФаза 3
- Texas Oncology - San Antonio, San Antonio
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Се регрутираФаза 2/3
- Local Institution - 0173, San Antonio
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Се регрутираФаза 1/2
- START San Antonio (STSA), San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Се регрутираФаза 1/2
- START South Texas Accelerated Research Therapeutics, San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Се регрутираФаза 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Се регрутираФаза 1/2
- START San Antonio, San Antonio
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2/3
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Се регрутираНабљудувачка студија
- The University of Texas Health Science Center at San Antonio, San Antonio
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Се регрутираФаза 1
- Site 102 - START San Antonio, San Antonio
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Се регрутираФаза 1/2
- START | San Antonio, San Antonio
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics, San Antonio
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Се регрутираФаза 1/2
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Се регрутираФаза 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- Research Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- START San Antonio, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- UT Health Mays Cancer Center, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- Clinical Trial Site, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Се регрутираФаза 1
- START - San Antonio, San Antonio
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Next Oncology, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Се регрутираФаза 1
- New Experimental Therapeutics of San Antonio LLC, San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Се регрутираФаза 3
- Jason Bates at University of Texas Health Science Center, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Се регрутираФаза 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Се регрутираФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- Start San Antonio, LLC, San Antonio
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- Research Site, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Се регрутираФаза 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- START, San Antonio
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Се регрутираФаза 1
- NEXT Oncology, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Се регрутираФаза 1/2
- Next Oncology, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Се регрутираФаза 2
- NEXT Oncology, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Се регрутираФаза 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Се регрутираФаза 1/2
- Research Site, San Antonio
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- START San Antonio, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Се регрутираФаза 1/2
- START San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Се регрутираФаза 1/2
- Next Oncology, San Antonio, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Се регрутираФаза 1
- Dren Investigational Site, San Antonio
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- Columbus, OH57 студии
- Washington, DC55 студии
- Seattle, WA53 студии
Други студии во San Antonio
- Рак на дојка47 студии
- Колоректален карцином46 студии
- Метастатски карцином44 студии
- Рак (сите типови)41 студија
- Дебелина40 студии
- Дијабетес тип 237 студии
- Прекумерна телесна тежина34 студии
- Карцином на јајниците31 студија
- Карцином на панкреасот31 студија
- Рак на простата28 студии
- Рак на ендометриумот27 студии
- Рак на бели дробови26 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.